NCT02530034
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 36 versions: 22 with changes below, 14 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Stopped Trial terminated Sponsor's reason: FDA Clinical Hold
- Final enrollment: 15 participants (planned 72)
- Primary completion date changed from estimate of Jan 1, 2027 to Oct 15, 2026
- Notable Eligibility criteria expanded, about 7 words
- Interventions: Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4 (Drug), Laboratory Biomarker Analysis (Other), Pharmacological Study (Other) to Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4 (Drug), Laboratory Biomarker Analysis (Other), Pharmacological Study (Other)
- Secondary endpoints: details revised at 1 of 4 entries
- Notable Primary and study completion dates: Jan 31, 2026 to Jan 1, 2027v33
- Study Identification, Study Status, Conditionsv31
- Study Identification, Study Status, Conditionsv30
Show 16 earlier versionsHide 16 earlier versions
- Notable Primary and study completion dates: Jan 30, 2024 to Jan 31, 2026v28
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 4 of 4 sites
- Minor Study sites: 3 to 4v24
- Minor Study sites: 1 to 3v22
- Notable Primary and study completion dates: Jan 31, 2022 to Jan 30, 2024v21
- Notable Eligibility criteria expanded, about 20 words
- Site contact updated
- Notable Eligibility criteria shortened, about 31 words
- Primary endpoints: 1 to 2
- Enrollment target: 60 to 72
- Study description expanded, about 1 word
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
Notable Primary endpoints: 2 to 1v9 Show 10 more changesShow less
- Eligibility criteria shortened, about 1 word
- Primary and study completion dates: Jan 2022 to Jan 31, 2022
- Start date: Jan 2019 to Jan 31, 2019
- Interventions: Hu8F4 (Drug) to Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4 (Drug), Laboratory Biomarker Analysis (Other), Pharmacological Study (Other)
- Secondary endpoints revised (4)
- Study description shortened, about 722 words
- Study site revised
- Collaborator revised
- Study arms: 4 to 1
- Study title shortened, about 3 words
- Notable Start date: Sep 2018 to Jan 2019
- Primary completion date: Sep 2021 to Jan 2022
- Study completion date: Sep 2022 to Jan 2022
- Site contact updated
Notable Start date: Jun 2018 to Sep 2018v7 Show 4 more changesShow less
- Eligibility criteria expanded, about 114 words
- Primary completion date: Jun 2021 to Sep 2021
- Study completion date: Jun 2022 to Sep 2022
- Study description expanded, about 51 words
- Notable Start date: Mar 2018 to Jun 2018
- Primary completion date: Mar 2021 to Jun 2021
- Study completion date: Mar 2021 to Jun 2022
- Minor Primary and study completion dates: Jan 2021 to Mar 2021
- Start date: Jan 2018 to Mar 2018
- Study description revised
Notable Start date: Nov 2016 to Jan 2018v4 Show 5 more changesShow less
- Primary endpoints: 1 to 2
- Primary completion date: Nov 2020 to Jan 2021
- Study completion date: Jan 2021
- Secondary endpoints expanded, about 35 words
- Study arms: 1 to 4
- Notable Start date: May 2016 to Nov 2016
- Primary completion date: May 2020 to Nov 2020
- Minor Primary completion date: Dec 2020 to May 2020
- Start date: Dec 2016 to May 2016
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Minimum safety data
Timeframe: 4 weeks
Biologically-effective dose
Timeframe: 4 weeks
Secondary (4)
Overall survival
Disease-free survival
Event-free survival
Duration of complete remission
Arms and interventions
Treatment (Hu8F4)Experimental
Patients receive anti-PR1/HLA-A2 monoclonal antibody Hu8F4 IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drugs: Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4
Other: Laboratory Biomarker Analysis, Pharmacological Study
Sites
4 sites in 1 country